The current pipeline of OncoBone Ventures includes three therapeutic assets that are co-developed with original inventors of the assets. In addition, several potential assets are under evaluation.
Click the to find out more about the therapeutic asset of each partner
OBP-001 is a first-in-class humanized immunomodulating antibody that has provided proof-of-concept for inhibiting breast cancer lung metastasis. OncoBone Ventures will study proof-of-concept for bone metastasis, followed by regulatory safety studies and finding an outlicensing partner for the asset.
OBP-002 is a first-in-class small molecule enzyme inhibitor with good pharmacological profile. Proof-of-concept studies are to be conducted, followed by regulatory safety studies and finding an outlicensing partner for the asset.
OBP-003 is a humanized antibody for a target that is an important regulator of tumor immune escape. Proof-of-concept studies for bone metastasis are to be conducted, followed by regulatory safety studies and finding outlicensing partner for the asset.
The company has identified other potential therapeutic assets for bone metastasis that are currently under evaluation.